Tryptamine-based human β3-adrenergic receptor agonists. Part 3: Improved oral bioavailability via modification of the sulfonamide moiety

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 4, 2005, Pages 1061-1064

  Sawa, Masaaki ^a   Mizuno, Kazuhiro ^a   Harada, Hiroshi ^a   Tateishi, Hirotaka ^a   Arai, Yukiyo ^a   Suzuki, Shinya ^a   Oue, Mayumi ^a   Tsujiuchi, Hiroshi ^a   Furutani, Yasuji ^a   Kato, Shiro ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Agonist; Tryptamine; 3 Adrenergic receptor

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; SULFONAMIDE; TRYPTAMINE;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG POTENCY; HUMAN; HUMAN CELL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 20144387873     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.12.033     Document Type: Article

References (11)

1. H. Harada, Y. Hirokawa, K. Suzuki, Y. Hiyama, M. Oue, H. Kawashima, N. Yoshida, Y. Furutani, and S. Kato Bioorg. Med. Chem. Lett. 13 2003 1301 1305
2. K. Mizuno, M. Sawa, H. Tateishi, H. Harada, M. Oue, H. Tsujiuchi, Y. Furutani, and S. Kato Bioorg. Med. Chem. Lett. 14 2004 5959 5962
3. M. Sawa, H. Tateishi, K. Mizuno, H. Harada, M. Oue, H. Tsujiuchi, Y. Furutani, and S. Kato Bioorg. Med. Chem. Lett. 14 2004 5963 5966
4. C.J. de Souza, and B.F. Burkey Curr. Pharm. Des. 7 2001 1433 1449
5. O. Yamaguchi Urology 59 Suppl 5A 2002 25 29
6. E. Ghera, A. Plemenitas, and Y. Ben-David Synthesis 1984 504 506
7. K.S.A. Vallin, M. Larhed, and A. Hallberg J. Org. Chem. 66 2001 4340 4343
8. 3-AR were prepared as described in Kato, S.; Harada, H.; Taoka, I.; Kawashima, H. PCT Patent Application, WO 2000044721, 2000
9. Kato, S.; Harada, H.; Hirokawa, Y.; Yoshida, N.; Kawashima, H. PCT Patent Application, WO 9616938, 1996
10. The apparent permeability coefficients (Papp) were determined in the apical-to-basolateral (A-to-B) direction across the cell's monolayers cultured on polycarbonate membrane filters
11. Compound 16i was dosed orally at 5 mg/kg in 1% hydroxypropyl cellulose aqueous solution and intravenously at 0.5 mg/kg in a vehicle consisting of 10% DMSO, 10% EtOH, 20% polyethylene glycol and saline. After dosing, blood samples were collected at 5 and 15 min (iv only), and 0.5, 1, 2, 4, 6, 8, 24 h (iv and po) to determine plasma drug concentrations by LC/MS/MS